Learn how you can stall the development of full-blown Multiple Myeloma with evidence-based nutritional and supplementation therapies.
Click the orange button to the right to learn more.
You or a family-member has been diagnosed with MGUS aka monoclonal gammopathy of undetermined Significance. You may be wondering if MGUS “runs” in families. According to the two studies linked below, relatives of MGUS patients have a higher risk of being diagnosed with MGUS themselves.
The devil is in the detail as the saying goes.
Monoclonal gammopathy of undetermined significance or MGUS (pre-myeloma) at a glance-
When I was diagnosed with multiple myeloma (MM), I had no increased genetic risks such as a relative with Monoclonal Gammopathy of Undermined Significance or MM but I did have HPV and I did work in a printing plant, both of which increase one’s risk of MM. Conventional therapies such as aggressive chemotherapy and an autologous stem cell transplant (ASCT) did little for me other than give me short, long-term and late stage side effects.
My point is that being diagnosed with MM, to a large degree, is beyond our control. However, once someone is diagnosed with MGUS there are evidence-based, non-toxic therapies that research has shown can reduce the risk of a full-blown MM diagnosis.
If you do not want to “watch and wait” to see if your pre-MM progresses to Multiple Myeloma please watch the short video below:
Consider MGUS Therapies such as:
“Monoclonal gammopathy of undetermined significance is present in ∼2% of individuals age >50 years. The increased risk of multiple myeloma (MM) in relatives of individuals with MGUS is consistent with Monoclonal gammopathy of undetermined significance being a marker of inherited genetic susceptibility to MM.
Common single-nucleotide polymorphisms (SNPs) at 2p23.3 (rs6746082), 3p22.1 (rs1052501), 3q26.2 (rs10936599), 6p21.33 (rs2285803), 7p15.3 (rs4487645), 17p11.2 (rs4273077), and 22q13.1 (rs877529) have recently been shown to influence MM risk.
To examine the impact of these 7 SNPs on Monoclonal gammopathy of undetermined significance , we analyzed two case-control series totaling 492 cases and 7306 controls. Each SNP independently influenced Monoclonal gammopathy of undetermined significance risk with statistically significant associations (P < .02) for rs1052501, rs2285803, rs4487645, and rs4273077. SNP associations were independent, with risk increasing with a larger number of risk alleles carried (per allele odds ratio, 1.18; P < 10(-7)). Collectively these data are consistent with a polygenic model of disease susceptibility to Monoclonal gammopathy of undetermined significance .”
“Monoclonal gammopathy of undetermined significance (MGUS), a precursor to multiple myeloma (MM), is one of the most common premalignant conditions in the general population. The cause of MGUS is largely unknown.
Recent studies show that there is an increased prevalence of MGUS in blood relatives of persons with lymphoproliferative and plasma cell proliferative disorders, suggesting presence of shared underlying genetic influences.
In the past few years, additional studies have examined risk factors and biologic characteristics that may contribute to the increased prevalence of MGUS among relatives of probands with MGUS, MM, and other blood malignancies…
The largest study to date that provided comparative data was an investigation of a Swedish population that examined the increased risk of both plasma cell and lymphoproliferative disorders among first-degree blood relatives of persons with and without MGUS.8
This population-based investigation involved 14 621 relatives of 4458 patients with MGUS and found an increased risk of MGUS among relatives of probands, compared with 58 387 relatives of 17 505 controls without MGUS (relative risk [RR] = 2.8; 95% CI, 1.4-5.6). ..
A similar study was conducted at the Mayo Clinic to assess the prevalence of MGUS in first-degree blood relatives of MM and MGUS probands.9 Relatives of 232 MM and 97 MGUS probands were studied. Serum samples from 911 blood relatives were screened for MGUS with the use of electrophoresis and immunofixation.
MGUS was detected in 6% of relatives (age- and sex-adjusted prevalence of 8.1%; 95% CI, 6.3-9.8). With the use of the Olmsted County MGUS prevalence study as a reference, it was found that relatives had a higher prevalence of MGUS, with a risk ratio of 2.6 (95% CI, 1.9-3.4) compared with the general population.
This increased risk was seen both in relatives of MM probands (RR = 2.0; 95% CI, 1.4-2.8) and MGUS probands (RR = 3.3; 95% CI, 2.1-4.8)…